Immunotherapy with agonistic anti-CD137: two sides of a coin.

Yonglian Sun, Jonathan H. Chen, Yangxin Fu

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


CD137 (4-1BB), a member of the TNF receptor superfamily, is an inducible T cell costimulatory receptor primarily expressed on activated CD4+ and CD8+ T cells. Agonistic monoclonal antibodies (mAbs) against CD137 greatly enhance T cell-mediated immune responses against many types of tumors and viruses. Surprisingly, these agonists also showed therapeutic effects in several autoimmune diseases. These findings suggest that in different disease environments, CD137 engagement with agonist mAb in vivo can diametrically modulate immune response outcomes. Therefore, CD137 agonists represent a promising immunotherapeutic approach to a wide array of disparate immune disorders. However, CD137's potency in modulating immune response necessitates caution when targeting CD137 clinically.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalCellular & molecular immunology
Issue number1
StatePublished - Feb 2004

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Immunotherapy with agonistic anti-CD137: two sides of a coin.'. Together they form a unique fingerprint.

Cite this